Earnings Call Summary | STAGEZERO LIFE SCIENCES LTD(SZLSF.US) Q1 2024 Earnings Conference
StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update
Canadian Investment Regulatory Organization Trading Halt - SZLS
StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
StageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial Results
StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
StageZero Life Sciences Partners With My One Medical Source and 1,000+ Medical Access Points in the USA
StageZero Life Sciences Ltd: INTERIM MDA EN
StageZero Life Sciences Ltd: INTERIM FINANCIAL STATEMENTSREPORT EN
StageZero Life Sciences, Ltd. Announces Temporary Repricing of Warrants Expiring in 2023 and 2024
StageZero Life Sciences, Ltd Announces Results of Resolutions at Annual and Special Meeting
StageZero Life Sciences, Ltd. Special and Annual General Meeting Conference Call
StageZero Life Sciences Ltd. GAAP EPS of -$0.02, Revenue of $0.8M
StageZero Life Sciences, Ltd Announces Q1 2023 Financial Results - 15.2% Growth in Revenue Over Q4 2022 - and Operational Update
StageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023
StageZero Life Sciences, Ltd Announces Q4 2022 and Year End Financial Results and Operational Update
StageZero to Issue Q4 2022 Financial Results on Friday March 31
StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30
Short Interest in StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) Grows By 934.5%
StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) Short Interest Down 46.9% in February